Skip to main content
BioCentury on BioBusiness
Feature Story

Afrezza's journey

A short history of MannKind's long road with Afrezza

By Stephen Hansen, Senior Writer

The journey from concept to approved drug for MannKind Corp.'s Afrezza inhaled insulin is one beset by multiple regulatory setbacks that saw the company - the brainchild of serial entrepreneur, Chairman and CEO Alfred Mann - burn through more than $1.6 billion in cash over the past 12 years.

Indeed, the company has sustained itself with Mann's deep pockets. Mann and his entities owned 40% of MannKind as of March 21. And as of March 31, the company also owed the Mann Group $49.5 million under a loan arrangement.

Full Article

200th Show

Subscribe Now
Free Trial